SCHEMBL7990205

SCHEMBL7990205

O=C(Nc1ccccc1)C(=O)c1c(-c2ccc(Br)cc2)cc2ccccn12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.59
THRB P10828 1/20 0.59
MAPT P10636 7/20 0.57
ALDH1A1 P00352 7/20 0.57
SMN1; SMN2 Q16637 5/20 0.57
LMNA P02545 3/20 0.57
HTT P42858 3/20 0.56
RAB9A P51151 5/20 0.49
KDM4E B2RXH2 3/20 0.49
KMT2A Q03164 4/20 0.47
TDP1 Q9NUW8 2/20 0.47
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
NPC1 O15118 3/20 0.41
MEN1 O00255 3/20 0.40
MAPK1 P28482 1/20 0.40
PKM P14618 1/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1647264 0.95 L3MBTL1 (0.62) L3MBTL1THRBMAPTALDH1A1SMN1; SMN2
SCHEMBL1644750 0.91 L3MBTL1 (0.69) L3MBTL1THRBMAPTALDH1A1SMN1; SMN2
SCHEMBL1645601 0.88 ALDH1A1 (0.63) L3MBTL1THRBMAPTALDH1A1SMN1; SMN2
SCHEMBL1645777 0.88 L3MBTL1 (0.59) L3MBTL1THRBMAPTALDH1A1SMN1; SMN2
SCHEMBL1645840 0.85 L3MBTL1 (0.46) L3MBTL1THRBMAPTALDH1A1SMN1; SMN2
SCHEMBL1646417 0.85 THRB (0.50) L3MBTL1THRBMAPTALDH1A1SMN1; SMN2
SCHEMBL1646412 0.84 L3MBTL1 (0.57) L3MBTL1THRBMAPTALDH1A1SMN1; SMN2
SCHEMBL1645605 0.84 L3MBTL1 (0.63) L3MBTL1THRBMAPTALDH1A1SMN1; SMN2
SCHEMBL1646040 0.83 L3MBTL1 (0.62) L3MBTL1THRBMAPTALDH1A1SMN1; SMN2
SCHEMBL1645379 0.83 THRB (0.65) L3MBTL1THRBMAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD. 2010-03-04 US disclosed
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD. 2010-03-04 US disclosed
WO-2009144473-A1 ANTIFUNGAL COMBINATION THERAPY F2G LIMITED (GB) 2009-12-03 WO disclosed
WO-2008062182-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD (GB) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS NAT1, AGXT, CYP1A2 L3MBTL1 1723/4885THRB 3788/4885MAPT 2950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.